You just read:

Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes

News provided by

Provention Bio, Inc.

Apr 09, 2019, 07:00 ET